康希诺生物(06185.HK)破伤风疫苗新药上市申请获国家药监局受理

阿斯达克财经
06 Feb

康希诺生物(06185.HK) 公布,公司研发的吸附破伤风疫苗的新药上市申请已于近日获得中国国家药品监督管理局出具的受理通知书。(sl/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-06 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10